Top Page
Nova Eye Medical
(Sydney:EYE)
Nova Eye Medical (EYE) vs. iShares MSCI Australia ETF (EWA)
Nova Eye Medical Business Overview & Revenue Model
Nova Eye Medical Financial Statement Overview
| Breakdown | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 23.32M | 17.02M | 13.38M | 13.39M | 12.77M |
| Gross Profit | 20.19M | 842.00K | -765.00K | 1.77M | -1.64M |
| EBITDA | -5.98M | -9.48M | -7.89M | -3.67M | -5.75M |
| Net Income | -8.79M | -15.29M | -7.50M | -4.36M | -6.99M |
Balance Sheet | |||||
| Total Assets | 29.88M | 30.36M | 36.63M | 41.99M | 116.74M |
| Cash, Cash Equivalents and Short-Term Investments | 6.15M | 7.42M | 8.00M | 17.80M | 95.65M |
| Total Debt | 3.35M | 1.53M | 1.94M | 3.70M | 3.34M |
| Total Liabilities | 8.55M | 7.17M | 6.23M | 6.66M | 16.16M |
| Stockholders Equity | 21.33M | 23.19M | 30.40M | 35.34M | 100.59M |
Cash Flow | |||||
| Free Cash Flow | -8.31M | -7.52M | -10.27M | -15.13M | 3.79M |
| Operating Cash Flow | -7.86M | -6.72M | -4.68M | -12.90M | 5.45M |
| Investing Cash Flow | -325.00K | -800.00K | -4.58M | -3.22M | 88.26M |
| Financing Cash Flow | 6.91M | 6.82M | -402.00K | -61.61M | -13.29M |
Nova Eye Medical Technical Analysis
Nova Eye Medical Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $41.20M | ― | -50.50% | ― | 39.08% | 53.31% | |
54 Neutral | AU$56.70M | ― | -8.08% | ― | -5.62% | -225.71% | |
52 Neutral | $7.59B | 0.18 | -63.14% | 2.16% | 16.34% | 0.64% | |
51 Neutral | AU$153.50M | ― | -58.61% | ― | ― | -74.88% | |
48 Neutral | AU$11.78M | ― | -98.08% | ― | -7.44% | 30.34% | |
47 Neutral | AU$43.37M | ― | -135.33% | ― | -27.58% | 33.69% | |
41 Neutral | AU$119.47M | ― | -35.20% | ― | 4.68% | -155.42% |
Nova Eye Medical Corporate Events
Nova Eye Medical Limited announced a correction in their Quarterly Activities and Appendix 4C Cash Flow Report for June 2025, adjusting the cash and cash equivalents figure to A$5,054,000. The company reported a record full-year revenue of A$29.2 million for FY25, a 23% increase from the previous year, with significant sales growth in the second half. The glaucoma segment achieved a positive EBITDA in the second half of FY25, and the company forecasts sales revenue between US$21 million to US$24 million for FY26, excluding China, aiming for breakeven EBITDA in the first half of FY26.
Nova Eye Medical Limited reported a record full-year revenue of A$29.2 million for the fiscal year 2025, marking a 23% increase from the previous year. The company’s glaucoma segment showed significant improvement with a positive EBITDA in the second half of FY25. The company also reduced its cash outflow from operations and aims for breakeven EBITDA in the first half of FY26, indicating a positive trajectory in financial performance and operational efficiency.
Nova Eye Medical Limited has announced an upcoming Investor Webinar scheduled for July 31, 2025, where Managing Director Tom Spurling will review the company’s June Quarterly Report. This event provides an opportunity for shareholders and interested parties to engage with the company, potentially impacting investor relations and market perception.
Nova Eye Medical Limited has announced the quotation of 7,000 fully paid ordinary securities on the Australian Securities Exchange (ASX) as part of an employee incentive scheme. This move is expected to enhance employee engagement and align their interests with company performance, potentially impacting the company’s operational dynamics and market positioning positively.
Nova Eye Medical Limited has announced an investor webinar, highlighting their commitment to transparency and engagement with stakeholders. The company is addressing the challenges associated with high intraocular pressure (IOP), which can lead to optic nerve damage and blindness, by focusing on solutions that prevent fluid buildup in the eye.
Nova Eye Medical Limited has reported record revenues of A$28.8 million for the fiscal year ending June 30, 2025, marking a 21% increase from the previous year. This growth is attributed to the strong performance of their iTrack™ Advance device, particularly in the US market, where sales increased by 25%. The company anticipates continued revenue growth in FY26, reflecting the growing global recognition of its technology and successful market penetration.
Nova Eye Medical Limited has announced an upcoming Investor Webinar scheduled for July 9, 2025, where Managing Director Tom Spurling will discuss the company’s sales results for the fiscal year 2025. This event provides an opportunity for stakeholders to engage with the company, potentially impacting investor relations and market perception of Nova Eye Medical’s performance and strategic direction.
Nova Eye Medical Limited has announced the cessation of 7,000 performance rights, as the conditions for these securities have not been met or have become incapable of being satisfied. This development may impact the company’s capital structure and could have implications for its stakeholders, reflecting a potential shift in the company’s operational or strategic focus.
Nova Eye Medical Limited has announced the application for quotation of 21,000 ordinary fully paid securities on the Australian Securities Exchange, issued under an employee incentive scheme. This move reflects the company’s ongoing efforts to enhance its market presence and incentivize its workforce, potentially impacting its operational dynamics and stakeholder engagement.
Nova Eye Medical Limited has announced an investor webinar, highlighting its commitment to delivering on promises by selling highly effective ophthalmic products that are in demand among eye surgeons. This announcement underscores the company’s strategic focus on capitalizing on a growing market, which could enhance its industry positioning and potentially benefit stakeholders.
Nova Eye Medical Ltd has issued 45,236 shares to an American consultant as part of a consulting agreement. This move, executed without the need for disclosure under the Corporations Act, signifies the company’s compliance with regulatory requirements and may enhance its operational capabilities and market positioning.
Nova Eye Medical Limited has announced the quotation of 45,236 ordinary fully paid securities on the ASX, effective May 6, 2025. This move is part of a consulting agreement in America aimed at enhancing clinical marketing, new product development, peer-to-peer education, and clinical investigations, which could strengthen the company’s market position and stakeholder engagement.
Nova Eye Medical has announced an upcoming Investor Webinar on 6 May 2025, where Managing Director Tom Spurling will discuss the company’s March 2025 Quarterly Activities and Cashflow Report. The report highlights record US sales, revenue growth, and improved profitability in glaucoma treatments. Additionally, Nova Eye Medical is exploring opportunities to expand its iTrack™ technology into ocular drug delivery markets, indicating potential future growth and innovation in their product offerings.
Nova Eye Medical Limited reported strong financial performance for the March 2025 quarter, with a 27% increase in sales compared to the previous corresponding period, excluding China. The company achieved record sales in the USA, contributing to a significant reduction in losses within the glaucoma segment. The company also identified potential growth opportunities in ocular drug delivery using its proprietary iTrack™ technology, further strengthening its market position.